Fate reports Phase I data for Fate-NK100 in ovarian cancer

Fate Therapeutics Inc. (NASDAQ:FATE) reported data from two evaluable patients with ovarian cancer in the Phase I APOLLO trial showing that Fate-NK100 led to stable disease with evidence of tumor reduction at day 28 in one patient with platinum-resistant stage III fallopian tube carcinoma. No dose-limiting toxicities were reported.

The open-label, dose-escalation, U.S. trial is enrolling about 16 patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Patients are receiving a single intraperitoneal infusion of Fate-NK100 given after outpatient chemotherapy and followed by a short course of intraperitoneal IL-2. The Masonic Cancer Center is sponsoring the trial...